



RHEUMATOLOGY

VOLUME 48 NUMBER 7 JULY 2009

www.rheumatology.oxfordjournals.org

- Musculoskeletal problems and work •
- Anti-TNF-induced lupus •
- Urinary FOXP3 mRNA in patients with lupus nephritis—relation with disease activity and treatment response •
- Complementary and alternative medicines in Raynaud's phenomenon •
- Treatment of sicca symptoms in Sjögren's syndrome •
- Allopurinol and mortality in hyperuricaemic patients •
- How safe is glucocorticoid therapy in rheumatoid arthritis? •
- Stiff skin syndrome •

ISSN 1462-0324

OXFORD  OPEN


OXFORD JOURNALS
OXFORD UNIVERSITY PRESS

RHEUMATOLOGY

Official Journal of the British Society for Rheumatology

Editor
R. J. Moots

Managing Editor
S. Ahmed

Senior Editorial Officer
K. Wilson

Editorial Assistant
T. Dudley

Editorial Office: Bride House, 18-20 Bride Lane, London EC4Y 8EE, UK. Tel +44 (0)20 7842 0902
Fax +44 (0)20 7842 0903; E-mail: editorial@rheumatology.org.uk

Associate Editors

M. Beresford
Liverpool
UK

Y. Chernajovsky
London
UK

D. Elewaut
Gent
Belgium

R. Fleischmann
Dallas
USA

A. C. Jones
Nottingham
UK

A. Kavanaugh
San Diego
USA

L. Kay
Newcastle
UK

R. Luqmani
Oxford
UK

M. Matucci-Cerinic
Florence
Italy

U. Müller-Ladner
Giessen/Bad Nauheim
Germany

Editorial Board

A. Adebajo, *Sheffield, UK*
S. Albiani, *San Diego, USA*
S. Bowman, *Birmingham, UK*
M. Brown, *Woolloongabba, Australia*
I. Bruce, *Manchester, UK*
C. Buckley, *Birmingham, UK*
R. Burgos-Vargas, *Mexico City, Mexico*
F. Buttgeriet, *Berlin, Germany*
L. Crofford, *Lexington, USA*
F. Cunha, *São Paulo, Brazil*
C. Denton, *London, UK*
O. Distler, *Zürich, Switzerland*
K. Dziedziejcz, *Keele, UK*
M. Ehrenstein, *London, UK*
H. El-Gabalawy, *Winnipeg, Canada*
O. FitzGerald, *Dublin, Ireland*

D. Foell, *Münster, Germany*
H. Foster, *Newcastle, UK*
S. Hall, *Malvern, Australia*
R. Handa, *New Delhi, India*
A. Hassell, *Stoke-on-Trent, UK*
E. Hay, *Keele, UK*
J. Highton, *Dunedin, NZ*
T. Huizinga, *Leiden, The Netherlands*
D. Isenberg, *London, UK*
C. Jorgensen, *Montpellier, France*
D. Kane, *Dublin, Ireland*
H.-Y. Kim, *Seoul, Republic of Korea*
G. Kitazawa, *Dudley, UK*
O. Kowal-Bielecka, *Białystok, Poland*
B. Lauwerys, *Brussels, Belgium*
E. Li, *Shatin, Hong Kong*

G. Macfarlane, *Aberdeen, UK*
J. Martin, *Granada, Spain*
D. McGonagle, *Leeds, UK*
R. Misra, *Lucknow, India*
E. Morand, *Melbourne, Australia*
T. Pap, *Münster, Germany*
C. Pitzalis, *London, UK*
G. Schett, *Vienna, Austria*
R. H. Straub, *Regensburg, Germany*
P.-P. Tak, *Amsterdam, The Netherlands*
T. Takeuchi, *Kawagoe, Japan*
P. C. Taylor, *London, UK*
M. Tikly, *Johannesburg, South Africa*
M. Underwood, *London, UK*
H. Xu, *Shanghai, China*
E. Thomas, *Keele, UK (Statistical Advisor)*

Ex-officio

D. Bax
(BSR President)

P. Thompson
(BSR Honorary Treasurer)

C. Pease
(BSR Honorary Secretary)

D. L. Scott
(BSR Honorary Heberden Librarian)

The journal is listed in *Current Contents/Life Sciences/Clinical Practice* · *Index Medicus* · *Medline* · *EMBASE/Excerpta Medica* · *Chemical Abstracts* · *Elsevier BIOBASE/Current Awareness in Biological Sciences*

SUBSCRIPTIONS

A subscription to *Rheumatology* comprises 12 issues. All prices include postage, and for subscribers outside the UK delivery is by Standard Air. *Rheumatology* Advance Access contains papers that have reached corrected proof stage, but have not yet been included within an issue. Advance Access is updated weekly.

Annual Subscription Rate (Volume 48, 12 issues, 2009): *Institutional – Academic/Non profit:* Print edition and site-wide online access: £591/US\$1182/€887; Print edition only: £561/US\$1122/€842; Site-wide online access only: £514/US\$1028/€771. *Institutional – Corporate:* Print edition and site-wide online access: £739/US\$1478/€1109; Print edition only: £702/US\$1404/€1053; Site-wide online access only: £643/US\$1286/€965. *Personal:* Print edition (includes free online access): £591/US\$1182/€887. Please note: £ Sterling and Euro rates apply in Europe, US\$ elsewhere. There may be other subscription rates available, for a complete listing please visit www.rheumatology.oxfordjournals.org/subinfo. Full prepayment, in the correct currency, is required for all orders. Orders are regarded as firm and payments are not refundable. Subscriptions are accepted and entered on a complete volume basis. Claims cannot be considered more than FOUR months after publication or date of order, whichever is later. All subscriptions in Canada are subject to GST. Subscriptions in the EU may be subject to European VAT. If registered, please supply details to avoid unnecessary charges. For subscriptions that include online versions, a proportion of the subscription price may be subject to UK VAT. Personal rate subscriptions are only available if payment is made by personal cheque or credit card and delivery is to a private address.

The current year and two previous years' issues are available from Oxford University Press. Previous volumes can be obtained from the Periodicals Service Company, 11 Main Street, Germantown, NY 12526, USA. Email: psc@periodicals.com. Tel: +1 (518) 537 4700. Fax: +1 (518) 537 5899.

For further information, please contact: Journals Customer Service Department, Oxford University Press, Great Clarendon Street, Oxford OX2 6DP, UK. Email: jnls.cust.serv@oxfordjournals.org. Tel (and answerphone outside normal working hours): +44 (0)1865 353907. Fax: +44 (0)1865 353485. **In the US, please contact:** Journals Customer Service Department, Oxford University Press, 2001 Evans Road, Cary, NC 27513, USA. Email: jnlorders@oxfordjournals.org. Tel (and answerphone outside normal working hours): 800 852 7323 (toll-free in USA/Canada). Fax: 919 677 1714. **In Japan, please contact:** Journals Customer Services, Oxford University Press, 4-5-10-8F Shiba, Minato-ku, Tokyo, 108-8386, Japan. Email: custserv.jp@oxfordjournals.org. Tel: +81 3 5444 5858. Fax: +81 3 3454 2929.

Methods of payment. (i) Cheque (payable to Oxford University Press, to Oxford University Press, Cashiers Office, Great Clarendon Street, Oxford OX2 6DP, UK) in GB£ Sterling (drawn on a UK bank), US\$ Dollars (drawn on a US bank), or EU€ Euros. (ii) Bank transfer to Barclays Bank Plc, Oxford Group Office, Oxford (bank sort code 20-65-18) (UK), overseas only Swift code BARC GB 22 (GB£ Sterling to account no. 70299332, IBAN GB89BARC20651870299332; US\$ Dollars to account no. 66014600, IBAN GB27BARC20651866014600; EU€ Euros to account no. 78923655, IBAN GB16BARC20651878923655). (iii) Credit card (Mastercard, Visa, Switch or American Express).

Rheumatology is published monthly by Oxford University Press, Oxford, UK. Annual subscription price is £528/US\$1056/€792. *Rheumatology* is distributed by Mercury International, 365 Blair Road, Avenel, NJ 07001, USA. Periodicals postage paid at Rahway, NJ and at additional entry points.

US Postmaster: send address changes to *Rheumatology* (ISSN 1462-0324), c/o Mercury International, 365 Blair Road, Avenel, NJ 07001, USA.

Supplements, reprints and corporate sales: For requests from industry and companies regarding supplements, bulk article reprints, sponsored subscriptions, translation opportunities for previously published material, and corporate online opportunities, please email special.sales@oxfordjournals.org, fax +44 (0)1865 353774 or visit www.oxfordjournals.org/jnls/sales.

For information about DOIs and how to resolve them, please visit <http://dx.doi.org>.

Permissions: For information on how to request permissions to reproduce articles/information from this journal, please visit www.oxfordjournals.org/jnls/permissions.

Advertising: Advertising, inserts and artwork enquiries should be addressed to Advertising and Special Sales, Oxford Journals, Oxford University Press, Great Clarendon Street, Oxford, OX2 6DP, UK. Tel: +44 (0)1865 354767; Fax: +44 (0)1865 353774; E-mail: jnlsadvertising@oxfordjournals.org

Drug disclaimer. The mention of trade names, commercial products or organizations, and the inclusion of advertisements in the journal does not imply endorsement by *Rheumatology*, the editors, the editorial board, Oxford University Press or the organization to which the authors are affiliated. The editors and publishers have taken all reasonable precautions to verify drug names and doses, the results of experimental work and clinical findings published in the journal. The ultimate responsibility for the use and dosage of drugs mentioned in the Journal and in interpretation of published material lies with the medical practitioner, and the editors and publishers cannot accept liability for damages arising from any errors or omissions in the journal. Please inform the editors of any errors.

Material disclaimer. The opinions expressed in *Rheumatology* are those of the authors and contributors, and do not necessarily reflect those of the British Society of Rheumatology, the editors, the editorial board, Oxford University Press or the organization to which the authors are affiliated.

© British Society for Rheumatology 2009

All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission of the Publishers, or a licence permitting restricted copying issued in the UK by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1P 9HE, or in the USA by the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923. For those in the USA or Canada not registered with CCC, articles can be obtained by fax in 48 hours by calling: WISE for Medicine™ 1-800-667-WISE.

INSTRUCTIONS TO AUTHORS

For instructions on how to submit papers to *Rheumatology*, please refer to the journal website at <http://www.rheumatology.oxfordjournals.org>

Front cover:

Left: 3D reconstructed computerised tomography angiogram showing dilatation of the ascending aorta and arch in a patient with relapsing polychondritis complicated by aortitis. From Seymour MW, Home DM, Williams RO and Allard SA. Prolonged response to anti-tumour necrosis factor treatment with adalimumab (Humira) in relapsing polychondritis complicated by aortitis. *Rheumatology* 2007;46:1738–1739.

Middle: HE staining of femurs from rabbits treated with MPSSL+BMT, showing no osteonecrosis findings except for a few empty lacunae within the normal bone trabeculae or fat cells. From Asada T, Kushida T, Umeda M, Oe K, Matsuya H, Wada T, Sasai K, Ikehara S and Iida H. Prevention of corticosteroid-induced osteonecrosis in rabbits by intra-bone marrow injection of autologous bone marrow cells. *Rheumatology* 2008;47:591–596.

Right: Confocal micrograph showing an improvement of cutaneous vasculature and innervation in a patient with scleroderma after treatment with prostacyclin analogue. From Provitera V, Nolano M, Pappone N, Lubrano E, Stancanelli A, Lanzillo B and Santoro L. Axonal degeneration in systemic sclerosis can be reverted by factors improving tissue oxygenation. *Rheumatology* 2007;46:1739–1741.

Typeset by the Cepha Imaging Pvt Ltd, Bangalore, India

Printed by Bell and Bain Ltd, Glasgow, UK